Active Sites Display

WP_094236619.1:JDJFOMJM_02154
Sequence length: 1080 aa
4 domain hit(s)
This protein was scanned against CAZyme family profile alignments to identify conserved domains. Each hit below shows a region of the query that aligns to a known CAZyme family. Within each family profile, certain residues are known or predicted to be catalytic — directly involved in the enzyme's chemical reaction. The sequence display compares these critical positions between the query protein and the family consensus:
Match: the query has the expected catalytic residue, suggesting this active site is conserved and likely functional.
Mismatch: the query has a different residue at this position, which may indicate altered activity, a non-functional site, or subfamily variation.
Gap: the catalytic position in the profile has no corresponding residue in the query alignment, suggesting a deletion or truncation in this region.
Match
Mismatch
Gap
Active Site Conservation Analysis
EntryClassNameDomain RangeCoverageConservationCat. SitesMatches
IPR001919CBMCarbohydrate-binding type-2 domain1–108074.6%52.4%84
IPR000514GHGlycoside hydrolase, family 391–156100%60%11
IPR001329GHGlycoside hydrolase family 56, bee venom hyaluronidase2–15100%40%31
PF03633GHGlycosyl hydrolase family 65, C-terminal domain544–91298.5%62.5%00
Domain coverage (1–1080 aa)
IPR001919 — Carbohydrate-binding type-2 domain (domain 1–1080)
Cross-ref: Pfam: PF00553
GO: GO:0004553 hydrolase activity, hydrolyzing O-glycosyl compoundsGO:0030246 carbohydrate bindingGO:0005975 carbohydrate metabolic process
1 11 21 31 41 51 61 71 81 91 101 111 121 131 141 151 161 171 181 191 201 211 221 231 241 251 261 271 281 291 301 311 321 331 341 351 361 371 381 391 401 411 421 431 441 451 461 471 481 491 501 511 521 531 541 551 561 571 581 591 601 611 621 631 641 651 661 671 681 691 701 711 721 731 741 751 761 771 781 791 801 811 821 831 841 851 861 871 881 891 901 911 921 931 941 951 961 971 981 991 1001 1011 1021 1031 1041 1051 1061 1071 Query: MTTSNTHTIH EDEVYELRAS FAQQRMWVLD QFSPGNPFYN MPNAVRLQGK LDLDALTDTI NEMIYRHETL RTSFEMLEDG LKQLVNAELV VEIPITDLQY LPLEERFPKA QELAKEEFAR PFLIKQAPLV RTRLLRLAAD DHMLLITMHH IISDGWSMGV FFTELAAIYE AFAKGQPSPL PDLTIQYADF SEWQFNYLTG DVLEKQLSYW KNTLGGSMPI LQLPTDKQRP VVQSYRGTVY KHMLSGDLLK KLQDFNQQER VTMFMTMLAA FNVLLARWTG QEDIWVGTPI AGRNVNGIEK LIGLFVNTLV MRADLSENVS FRDLLQRVQK DALDAFEHQD FPFEKLVEEL QPERNRTYSP LFQVFFAMQN TPREEVHLQD VTLSTVPHES GTAKFDLSLF CSELPDGLLC GFEYCTDLFE ESTIARMAEH FTHLVSSLLD NPDTPVYDLQ MLTDAEQQLF KTWNGELPAP ADSCVHRLIE EQAARTPDNI AVECERQTLT YRELNARANQ LARHLQTLGI GTESLVTLCV ERSIDLIVAE LGILKAGAAY VPIDPSNPAE RTAFILQDTK ASVMVTQSHL AQELPAHDAR LICLDTDGET LSGYATDNLV TDVTSQNLAY LIYTSGSTGT PKAVAVEHHQ LLSTLFAMQK TCGFTADDVM TWVVSVAFDV SLFEVMNPLL IGARVKVLTR AHITNLELLT EELQEVTTMH AVPSLMRQIV DAGRKAKENG ANFDKLRQLY SAGDVVSPQL LKDMNEVFHN AESYVLYGPT ETSIFATEYL AKRGQEGEKY TIGTRCANAQ LYVCDRFGKE VPLGVPGELH IAGLGVTRGY YGREELTAEK FITVNGERRY KSGDLVRFLP DGNIEFFGRM DGQVKIRGFR VEIGEIETVL VRHEQVKEAV LTVFEHQGEK NLAAYLVAEP GQTPDEALLR DFLKQTLPEY MVPAVFVTLQ EFPLNANGKI DRKALPAPGG VLTSANRPYI KPRTELEEQV AAMFGELLGI EQVGAADNFF ERGGHSLLAT MFVSRVKEAH KIEYSLGDLF EVATVEGIAA KIESRKGTAV SDGGAGMIKR IDRSRPMGGR Profile: ····N····· ·········· ··D······· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ···N······ ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·······N·· ·········· ·········· ·········· ·········· ····N··Y·· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ······C···
query > profilegap>T2N5>N32Q23>D49N464>N59N798>N79N845>N110R848>Y113M1077>C115
IPR000514 — Glycoside hydrolase, family 39 (domain 1–156)
Cross-ref: InterPro: IPR000514
GO: GO:0004553 hydrolase activity, hydrolyzing O-glycosyl compoundsGO:0005975 carbohydrate metabolic process
1 11 21 31 41 51 61 71 81 91 101 111 121 131 141 151 161 171 181 191 201 211 221 231 241 251 261 271 281 291 301 311 321 331 341 351 361 371 381 391 401 411 421 431 441 451 461 471 481 491 501 511 521 531 541 551 561 571 581 591 601 611 621 631 641 651 661 671 681 691 701 711 721 731 741 751 761 771 781 791 801 811 821 831 841 851 861 871 881 891 901 911 921 931 941 951 961 971 981 991 1001 1011 1021 1031 1041 1051 1061 1071 Query: MTTSNTHTIH EDEVYELRAS FAQQRMWVLD QFSPGNPFYN MPNAVRLQGK LDLDALTDTI NEMIYRHETL RTSFEMLEDG LKQLVNAELV VEIPITDLQY LPLEERFPKA QELAKEEFAR PFLIKQAPLV RTRLLRLAAD DHMLLITMHH IISDGWSMGV FFTELAAIYE AFAKGQPSPL PDLTIQYADF SEWQFNYLTG DVLEKQLSYW KNTLGGSMPI LQLPTDKQRP VVQSYRGTVY KHMLSGDLLK KLQDFNQQER VTMFMTMLAA FNVLLARWTG QEDIWVGTPI AGRNVNGIEK LIGLFVNTLV MRADLSENVS FRDLLQRVQK DALDAFEHQD FPFEKLVEEL QPERNRTYSP LFQVFFAMQN TPREEVHLQD VTLSTVPHES GTAKFDLSLF CSELPDGLLC GFEYCTDLFE ESTIARMAEH FTHLVSSLLD NPDTPVYDLQ MLTDAEQQLF KTWNGELPAP ADSCVHRLIE EQAARTPDNI AVECERQTLT YRELNARANQ LARHLQTLGI GTESLVTLCV ERSIDLIVAE LGILKAGAAY VPIDPSNPAE RTAFILQDTK ASVMVTQSHL AQELPAHDAR LICLDTDGET LSGYATDNLV TDVTSQNLAY LIYTSGSTGT PKAVAVEHHQ LLSTLFAMQK TCGFTADDVM TWVVSVAFDV SLFEVMNPLL IGARVKVLTR AHITNLELLT EELQEVTTMH AVPSLMRQIV DAGRKAKENG ANFDKLRQLY SAGDVVSPQL LKDMNEVFHN AESYVLYGPT ETSIFATEYL AKRGQEGEKY TIGTRCANAQ LYVCDRFGKE VPLGVPGELH IAGLGVTRGY YGREELTAEK FITVNGERRY KSGDLVRFLP DGNIEFFGRM DGQVKIRGFR VEIGEIETVL VRHEQVKEAV LTVFEHQGEK NLAAYLVAEP GQTPDEALLR DFLKQTLPEY MVPAVFVTLQ EFPLNANGKI DRKALPAPGG VLTSANRPYI KPRTELEEQV AAMFGELLGI EQVGAADNFF ERGGHSLLAT MFVSRVKEAH KIEYSLGDLF EVATVEGIAA KIESRKGTAV SDGGAGMIKR IDRSRPMGGR Profile: ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· D········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ··········
query > profileD141>D3
IPR001329 — Glycoside hydrolase family 56, bee venom hyaluronidase (domain 2–15)
Cross-ref: InterPro: IPR001329
GO: GO:0004415 hyalurononglucosaminidase activityGO:0006952 defense response
1 11 21 31 41 51 61 71 81 91 101 111 121 131 141 151 161 171 181 191 201 211 221 231 241 251 261 271 281 291 301 311 321 331 341 351 361 371 381 391 401 411 421 431 441 451 461 471 481 491 501 511 521 531 541 551 561 571 581 591 601 611 621 631 641 651 661 671 681 691 701 711 721 731 741 751 761 771 781 791 801 811 821 831 841 851 861 871 881 891 901 911 921 931 941 951 961 971 981 991 1001 1011 1021 1031 1041 1051 1061 1071 Query: MTTSNTHTIH EDEVYELRAS FAQQRMWVLD QFSPGNPFYN MPNAVRLQGK LDLDALTDTI NEMIYRHETL RTSFEMLEDG LKQLVNAELV VEIPITDLQY LPLEERFPKA QELAKEEFAR PFLIKQAPLV RTRLLRLAAD DHMLLITMHH IISDGWSMGV FFTELAAIYE AFAKGQPSPL PDLTIQYADF SEWQFNYLTG DVLEKQLSYW KNTLGGSMPI LQLPTDKQRP VVQSYRGTVY KHMLSGDLLK KLQDFNQQER VTMFMTMLAA FNVLLARWTG QEDIWVGTPI AGRNVNGIEK LIGLFVNTLV MRADLSENVS FRDLLQRVQK DALDAFEHQD FPFEKLVEEL QPERNRTYSP LFQVFFAMQN TPREEVHLQD VTLSTVPHES GTAKFDLSLF CSELPDGLLC GFEYCTDLFE ESTIARMAEH FTHLVSSLLD NPDTPVYDLQ MLTDAEQQLF KTWNGELPAP ADSCVHRLIE EQAARTPDNI AVECERQTLT YRELNARANQ LARHLQTLGI GTESLVTLCV ERSIDLIVAE LGILKAGAAY VPIDPSNPAE RTAFILQDTK ASVMVTQSHL AQELPAHDAR LICLDTDGET LSGYATDNLV TDVTSQNLAY LIYTSGSTGT PKAVAVEHHQ LLSTLFAMQK TCGFTADDVM TWVVSVAFDV SLFEVMNPLL IGARVKVLTR AHITNLELLT EELQEVTTMH AVPSLMRQIV DAGRKAKENG ANFDKLRQLY SAGDVVSPQL LKDMNEVFHN AESYVLYGPT ETSIFATEYL AKRGQEGEKY TIGTRCANAQ LYVCDRFGKE VPLGVPGELH IAGLGVTRGY YGREELTAEK FITVNGERRY KSGDLVRFLP DGNIEFFGRM DGQVKIRGFR VEIGEIETVL VRHEQVKEAV LTVFEHQGEK NLAAYLVAEP GQTPDEALLR DFLKQTLPEY MVPAVFVTLQ EFPLNANGKI DRKALPAPGG VLTSANRPYI KPRTELEEQV AAMFGELLGI EQVGAADNFF ERGGHSLLAT MFVSRVKEAH KIEYSLGDLF EVATVEGIAA KIESRKGTAV SDGGAGMIKR IDRSRPMGGR Profile: ···CH····· ··E······· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ··········
query > profileS4>C3N5>H4E13>E12
PF03633 — Glycosyl hydrolase family 65, C-terminal domain (domain 544–912)
1 11 21 31 41 51 61 71 81 91 101 111 121 131 141 151 161 171 181 191 201 211 221 231 241 251 261 271 281 291 301 311 321 331 341 351 361 371 381 391 401 411 421 431 441 451 461 471 481 491 501 511 521 531 541 551 561 571 581 591 601 611 621 631 641 651 661 671 681 691 701 711 721 731 741 751 761 771 781 791 801 811 821 831 841 851 861 871 881 891 901 911 921 931 941 951 961 971 981 991 1001 1011 1021 1031 1041 1051 1061 1071 Query: MTTSNTHTIH EDEVYELRAS FAQQRMWVLD QFSPGNPFYN MPNAVRLQGK LDLDALTDTI NEMIYRHETL RTSFEMLEDG LKQLVNAELV VEIPITDLQY LPLEERFPKA QELAKEEFAR PFLIKQAPLV RTRLLRLAAD DHMLLITMHH IISDGWSMGV FFTELAAIYE AFAKGQPSPL PDLTIQYADF SEWQFNYLTG DVLEKQLSYW KNTLGGSMPI LQLPTDKQRP VVQSYRGTVY KHMLSGDLLK KLQDFNQQER VTMFMTMLAA FNVLLARWTG QEDIWVGTPI AGRNVNGIEK LIGLFVNTLV MRADLSENVS FRDLLQRVQK DALDAFEHQD FPFEKLVEEL QPERNRTYSP LFQVFFAMQN TPREEVHLQD VTLSTVPHES GTAKFDLSLF CSELPDGLLC GFEYCTDLFE ESTIARMAEH FTHLVSSLLD NPDTPVYDLQ MLTDAEQQLF KTWNGELPAP ADSCVHRLIE EQAARTPDNI AVECERQTLT YRELNARANQ LARHLQTLGI GTESLVTLCV ERSIDLIVAE LGILKAGAAY VPIDPSNPAE RTAFILQDTK ASVMVTQSHL AQELPAHDAR LICLDTDGET LSGYATDNLV TDVTSQNLAY LIYTSGSTGT PKAVAVEHHQ LLSTLFAMQK TCGFTADDVM TWVVSVAFDV SLFEVMNPLL IGARVKVLTR AHITNLELLT EELQEVTTMH AVPSLMRQIV DAGRKAKENG ANFDKLRQLY SAGDVVSPQL LKDMNEVFHN AESYVLYGPT ETSIFATEYL AKRGQEGEKY TIGTRCANAQ LYVCDRFGKE VPLGVPGELH IAGLGVTRGY YGREELTAEK FITVNGERRY KSGDLVRFLP DGNIEFFGRM DGQVKIRGFR VEIGEIETVL VRHEQVKEAV LTVFEHQGEK NLAAYLVAEP GQTPDEALLR DFLKQTLPEY MVPAVFVTLQ EFPLNANGKI DRKALPAPGG VLTSANRPYI KPRTELEEQV AAMFGELLGI EQVGAADNFF ERGGHSLLAT MFVSRVKEAH KIEYSLGDLF EVATVEGIAA KIESRKGTAV SDGGAGMIKR IDRSRPMGGR Profile: ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ··········
query > profile
↑ Top





v1.01 @copyright 2026 UCLA